Get started
Author

Jozef Michalka

Observed names: J. Michalka, JOZEF MICHALKA
ORCID: 0000-0001-5959-2539
Observed ORCID: 0000-0001-5959-2539
OpenAlex ID: A5017350797
Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia
2019 · Zdeněk Král, Jozef Michalka, et al. · Journal of Cancer · 13
PDF
Diagnosis of Bloom Syndrome in a Patient with Short Stature, Recurrence of Malignant Lymphoma, and Consanguineous Origin
2020 · Jakub Trizuljak, Terezie Petruchová, et al. · Molecular Syndromology · 10
PDF
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
2023 · Sanjal H. Desai, Michael A Spinner, et al. · Blood Advances · 8
PDF
Castleman Disease: Retrospective Single-Center Study of Therapeutic Results in 10 Patients
2013 · Szturz Petr, Zdeněk Adam, et al. · Klinicka onkologie · 6
PDF
Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
2015 · Heidi Mocikova, Robert Pytlik, et al. · Acta Haematologica · 5
PDF
Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety
2025 · Kateřina Dědečková, Michal Andrlik, et al. · Radiotherapy and Oncology · 4
Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients
2020 · Vít K Procházka, Štěpánka Matuštíková, et al. · Blood · 4
Treatment and Prognosis of Relapsed or Refractory Hodgkin Lymphoma Patients Ineligible for Stem Cell Transplantation
2014 · Heidi Móciková, Alice Sýkorová, et al. · Klinicka onkologie · 4
PDF
Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)
2022 · A. Janikova, J. Michalka, et al. · Annals of Hematology · 3
P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
2022 · Jozef Michalka, Jana Marková, et al. · HemaSphere · 2
Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals
2019 · Vit K Prochazka, David Belada, et al. · Blood · 2
The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?
2010 · Andrea Janikova, Boris Tichy, et al. · Blood · 2
FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis
2025 · Prokop Vodicka, Matthew Maurer, et al. · Blood · 1
PDF
Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts
2025 · Prokop Vodicka, Yucai Wang, et al. · Blood · 1
Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
2024 · Sanjal H. Desai, Michael A Spinner, et al. · Blood · 1
Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?
2023 · Magdalena Klanova, Samuel Hricko, et al. · Blood · 1
Efficacy of brentuximab consolidation by metabolic response in an international real‐world cohort of classic Hodgkin lymphoma at high risk for progression after ASCT
2023 · S. H. Desai, A. Smith, et al. · Hematological Oncology · 1
PDF
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
2020 · Vít Procházka, David Belada, et al. · eJHaem · 1
First‐line Adjuvant Radiotherapy Improves Pfs in Primary Mediastinal Large B‐cell Lymphoma ‐ a Retrospective Analysis of 102 Patients From a Single Center
2019 · D. Salek, A. Janikova, et al. · Hematological Oncology · 1
Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients
2015 · Vit Prochazka, Tereza Dyskova, et al. · Blood · 1
Vitamin D insufficiency is not associated with diseaseaggressivity in newly diagnosed non-Hodgkin lymphoma patients
2013 · Miroslav Tomíška, Šárka Novotná, et al. · 1
Extranodal Involvement in Hodgkin’s Lymphoma: A Retrospective Analysis of Survival Outcomes and Prognostic Factors at a Single-Center Study
2026 · Eva Maule, Jozef Michalka, et al. · Bratislavské lekárske listy/Bratislava medical journal
PDF
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma
2026 · Sanjal H. Desai, Susan M. Geyer, et al. · Blood Cancer Journal
PDF
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEPA) in newly diagnosed CD30-positive peripheral T-cell lymphomas with integrated ctDNA analysis: Results of the phase 2 CHEPA trial.
2026 · Marek Trněný, Pavel Klener, et al. · Journal of Clinical Oncology
PDF
Treatment outcomes of Hodgkin lymphoma in the Czech Republic
2026 · Heidi Móciková, Jozef Michalka, et al. · Klinicka onkologie
PDF
Works count: 59
Citation count: 72
H-index: 5
I10-index: 2
Year
Topic
Type